FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963966870> ?p ?o ?g. }

• W1963966870 endingPage "16" @default.
• W1963966870 startingPage "11" @default.
• W1963966870 abstract "Objective To determine the effectiveness and safety of colesevelam hydrochloride (HCl) and ezetimibe combination therapy in statin-intolerant patients with dyslipidemia and diabetes mellitus (DM) or metabolic syndrome (MS). Methods We identified potential study subjects through a computerized text search of patient electronic medical records using the terms colesevelam, WelChol, ezetimibe, and Zetia. Medical records were subsequently reviewed to identify all patients with DM or MS. Baseline total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and triglyceride levels immediately before the initiation of therapy with colesevelam HCl (1.875 g twice a day) or ezetimibe (10 mg daily) were compared with those after a minimum of 3 months of single drug therapy and after a minimum of 3 months of combination therapy. Drug safety was evaluated by review of transaminase levels and reports of side effects or drug discontinuation. Results The computerized search initially identified 91 electronic medical records; 16 patients fulfilled all study criteria. Baseline patient demographics included a mean age of 62.5 (±11.8) years and a mean body mass index of 31.4 (±5.2) kg/m2; 50% of patients were female, 75% had type 2 DM, and 25% had MS. In comparison with baseline, colesevelam HCl-ezetimibe combination therapy was associated with significant reductions in mean levels of total cholesterol (27.5%), LDL-C (42.2%), and non-HDL-C (37.1%). In addition, 50% of patients achieved the National Cholesterol Education Program Adult Treatment Panel III LDL-C target of less than 100 mg/dL. Therapy was well tolerated, with no significant changes in mean transaminase levels, no reports of myalgia, and no discontinuation of therapy. Conclusion Colesevelam HCl-ezetimibe combination therapy was associated with improved TC, LDL-C, and non-HDL-C lipid profiles and was well tolerated. Such therapy may be a reasonable consideration for statin-intolerant patients with DM or MS who have elevated cholesterol levels. (Endocr Pract. 2007;13:11-16)" @default.
• W1963966870 created "2016-06-24" @default.
• W1963966870 creator A5000942604 @default.
• W1963966870 creator A5038468673 @default.
• W1963966870 creator A5051921317 @default.
• W1963966870 creator A5072828158 @default.
• W1963966870 creator A5073143328 @default.
• W1963966870 date "2007-01-01" @default.
• W1963966870 modified "2023-10-17" @default.
• W1963966870 title "Colesevelam Hydrochloride-Ezetimibe Combination Lipid-Lowering Therapy in Patients with Diabetes or Metabolic Syndrome and a History of Statin Intolerance" @default.
• W1963966870 cites W1977447015 @default.
• W1963966870 cites W1977456203 @default.
• W1963966870 cites W1981710837 @default.
• W1963966870 cites W2002162566 @default.
• W1963966870 cites W2002894162 @default.
• W1963966870 cites W2014759828 @default.
• W1963966870 cites W2019519444 @default.
• W1963966870 cites W2022551895 @default.
• W1963966870 cites W2029158612 @default.
• W1963966870 cites W2031831221 @default.
• W1963966870 cites W2037016936 @default.
• W1963966870 cites W2055105660 @default.
• W1963966870 cites W2058778081 @default.
• W1963966870 cites W2059078444 @default.
• W1963966870 cites W2070745109 @default.
• W1963966870 cites W2078807483 @default.
• W1963966870 cites W2102899779 @default.
• W1963966870 cites W2103714496 @default.
• W1963966870 cites W2106343349 @default.
• W1963966870 cites W2113284407 @default.
• W1963966870 cites W2125274568 @default.
• W1963966870 cites W2127307547 @default.
• W1963966870 cites W2133402021 @default.
• W1963966870 cites W2134068835 @default.
• W1963966870 cites W2139168645 @default.
• W1963966870 cites W2151152924 @default.
• W1963966870 cites W2154704322 @default.
• W1963966870 cites W2159449551 @default.
• W1963966870 cites W2166910397 @default.
• W1963966870 cites W424467158 @default.
• W1963966870 doi "https://doi.org/10.4158/ep.13.1.11" @default.
• W1963966870 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17360295" @default.
• W1963966870 hasPublicationYear "2007" @default.
• W1963966870 type Work @default.
• W1963966870 sameAs 1963966870 @default.
• W1963966870 citedByCount "47" @default.
• W1963966870 countsByYear W19639668702012 @default.
• W1963966870 countsByYear W19639668702013 @default.
• W1963966870 countsByYear W19639668702014 @default.
• W1963966870 countsByYear W19639668702015 @default.
• W1963966870 countsByYear W19639668702016 @default.
• W1963966870 countsByYear W19639668702017 @default.
• W1963966870 countsByYear W19639668702018 @default.
• W1963966870 countsByYear W19639668702020 @default.
• W1963966870 countsByYear W19639668702021 @default.
• W1963966870 countsByYear W19639668702022 @default.
• W1963966870 crossrefType "journal-article" @default.
• W1963966870 hasAuthorship W1963966870A5000942604 @default.
• W1963966870 hasAuthorship W1963966870A5038468673 @default.
• W1963966870 hasAuthorship W1963966870A5051921317 @default.
• W1963966870 hasAuthorship W1963966870A5072828158 @default.
• W1963966870 hasAuthorship W1963966870A5073143328 @default.
• W1963966870 hasConcept C126322002 @default.
• W1963966870 hasConcept C134018914 @default.
• W1963966870 hasConcept C2776839432 @default.
• W1963966870 hasConcept C2778096610 @default.
• W1963966870 hasConcept C2778163477 @default.
• W1963966870 hasConcept C2778402494 @default.
• W1963966870 hasConcept C2778657065 @default.
• W1963966870 hasConcept C2778715236 @default.
• W1963966870 hasConcept C2778913445 @default.
• W1963966870 hasConcept C2780578515 @default.
• W1963966870 hasConcept C555293320 @default.
• W1963966870 hasConcept C71924100 @default.
• W1963966870 hasConcept C90924648 @default.
• W1963966870 hasConceptScore W1963966870C126322002 @default.
• W1963966870 hasConceptScore W1963966870C134018914 @default.
• W1963966870 hasConceptScore W1963966870C2776839432 @default.
• W1963966870 hasConceptScore W1963966870C2778096610 @default.
• W1963966870 hasConceptScore W1963966870C2778163477 @default.
• W1963966870 hasConceptScore W1963966870C2778402494 @default.
• W1963966870 hasConceptScore W1963966870C2778657065 @default.
• W1963966870 hasConceptScore W1963966870C2778715236 @default.
• W1963966870 hasConceptScore W1963966870C2778913445 @default.
• W1963966870 hasConceptScore W1963966870C2780578515 @default.
• W1963966870 hasConceptScore W1963966870C555293320 @default.
• W1963966870 hasConceptScore W1963966870C71924100 @default.
• W1963966870 hasConceptScore W1963966870C90924648 @default.
• W1963966870 hasIssue "1" @default.
• W1963966870 hasLocation W19639668701 @default.
• W1963966870 hasOpenAccess W1963966870 @default.
• W1963966870 hasPrimaryLocation W19639668701 @default.
• W1963966870 hasRelatedWork W1918902660 @default.
• W1963966870 hasRelatedWork W1987424073 @default.
• W1963966870 hasRelatedWork W2023154173 @default.
• W1963966870 hasRelatedWork W2041561513 @default.
• W1963966870 hasRelatedWork W2079658706 @default.
• W1963966870 hasRelatedWork W2104058454 @default.

• next